| It would not be wrong to say that African swine fever is slowly changing the game of the US-China trade war. President Trump recently said that China had started buying American agricultural products, suggesting that the US-China trade war could end before next year’s US presidential election. [사진=픽사베이] |
[한국영농신문 이광조 기자]
The Agriculture, Forestry and Livestock Quarantine Headquarters (Director Bong-Gyun Park, hereinafter referred to as the Quarantine Headquarters) announced that it has developed the world’s first ‘immune-enhancing vaccine antigen platform’ that can maximize the effectiveness of the foot-and-mouth disease vaccine.
The ‘immune-enhancing vaccine antigen production platform’ developed this time induces strong adaptive immunity by strengthening the cell function responsible for the production of immune antibodies during foot-and-mouth disease vaccination. It plays a role in overcoming the phenomenon of interference with vaccine effect.
Currently, when vaccinated against foot-and-mouth disease vaccine for young pigs (less than 2 months of age), the antibody (parental antibody) delivered from the mother pig through colostrum intake may interfere with the active antibody formation by the vaccine (antigen), so the level of the maternal antibody It is recommended to be vaccinated after the age of 2 months, which is the point at which this decrease.
However, the level, titer, and half-life of the maternal antibody differ depending on the animal, so it was difficult to determine the appropriate time to vaccinate the foot-and-mouth disease in the field. was a factor that negatively affected the achievement of the prevention effect through the vaccine.
Accordingly, the Quarantine Headquarters developed a new concept of immune-enhancing foot-and-mouth disease vaccine antigen platform that can overcome the phenomenon of induction of strong adaptive (cellular and humoral) immune responses through strengthening the antigenicity of vaccines and overcoming the interference of maternal antibodies.
The newly developed vaccine antigen platform allows specific substances that can enhance the function of B cells, the immune cells responsible for the production of antibodies for immunity, to be expressed on the surface of the vaccine antigen. It has the feature of enhancing the immunogenicity of the foot-and-mouth disease vaccine antigen by directly stimulating B cells by fusion to the A-type surface structural protein.
In addition, a new next-generation vaccine was developed by applying the antigen platform technology developed this time. It was found that the next-generation new vaccine induces an improved adaptive immune response even when the maternal antibody is inoculated and then inoculated normally.
After inoculation with the new vaccine, the antibody increased to about 16-fold (foot-and-mouth disease type O) to 32-fold (foot-and-mouth disease type A) compared to the existing vaccine, and it was confirmed that the active substance responsible for cellular immunity also increased. These research results have been recognized for scientific and technological excellence and are published in international academic journals. Papers have been published in the latest online edition, and patent applications for the technology have also been made (two cases).
Park Jong-hyeon, head of the Foot and Mouth Disease Vaccine Research Center at the Quarantine Headquarters, said, “This study has laid the foundation for producing a high-quality, immune-enhancing foot-and-mouth disease vaccine that overcomes the technical limitations of imported and currently used foot-and-mouth disease vaccines. It is expected to be useful for developing vaccines for other animal infectious diseases in the future, while resolving difficulties in policy improvement and vaccination of farmers.”
Reporter Lee Kwang-jo lgj@youngnong.co.kr